Disclaimers & Cautionary Statements

Transcription

1

2 Disclaimers & Cautionary Statements The information found herein, and any other materials provided by Cronos Group (the Company ), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation. This information is confidential and should not be distributed, in whole or in part, beyond the recipient and its advisors. The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and information provided by unaffiliated third parties and is subject to change without notice. This document may contain forward-looking information and forward-looking statements within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forwardlooking statements are not guarantees of future performance. All forwardlooking information contained herein are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

3 Virtuous Cycle Distribution Capacity IP Portfolio Brands

4 Virtuous Cycle Capacity

5 STRATEGIC PRIORITIES Capacity 95 acres zoned for cannabis production, on-site well, natural gas co-gen line, and phase 3 power Over 150 unique genetics Good Manufacturing Practice ( GMP ) certification from Germany 7,000 kg of capacity within existing 70,000 sq. ft. Dealer s License enabling R&D of novel products, export of concentrated derivatives, and analytical testing

6 Capacity PEACE EXPANSION Expansion includes: a state-of-the- art 286,000 sq. ft. indoor production facility and a 1,200 sq. ft. extraction lab Indoor facility expected to be largest purpose-built indoor cannabis production facility in the world, fully operational by Summer 2018 STRATEGIC PRIORITIES Domestic capacity expected to reach over 40,000KG prior to 2019

7 STRATEGIC PRIORITIES Capacity Based in Okanagan Valley, BC with a 2,000 sq. ft. pilot facility 31 acres zoned for cannabis production with premium genetics sourced from WMMC On-site artesian well providing free source of water (200+ gallon per minute capacity) Entered industry first strategic joint venture with Canadian First Nations, Indigenous Roots Climate and power costs provide cost advantage over other Canadian jurisdictions

8 Capacity Strategic joint venture with Kibbutz Gan Shmuel, which already exports to 35 countries throughout Europe & Asia Ideal climate enables production of high quality medical cannabis at an expected cost of between $0.40 and $0.50/g STRATEGIC PRIORITIES Over 1,000 agriculturally skilled Kibbutz members live on site and existing infrastructure available to support operations Situated on 4,939 acres of mixed-use agricultural/industrial land, with ability to expand beyond 100,000 KG annually Phase 1: 45,000-sq. ft. greenhouse, 5,000 KG annually Phase 2: increase capacity to 24,000 KG annually

9 Virtuous Cycle Distribution

10 INCREMENTAL DISTRIBUTION Distribution GERMANY Exclusive supply agreement with Pohl-Boskamp, an international pharmaceutical manufacturer and supplier founded in 1835 Pohl distributes products to over 12,000 German pharmacies German parliament implemented health insurance coverage for patients Large shortage of medical cannabis exists in Germany STRATEGIC PRIORITIES Peace Naturals is exporting 12 different varieties

11 STRATEGIC PRIORITIES MEDICAL Underserved indigenous communities stand to benefit from medical cannabis access Distribution Most Indigenous health needs are covered by Non-Insured Health Benefits Program (NIHB) RECREATIONAL Industry first strategic joint venture with Canadian First Nations, led by Phil Fontaine to forming a new company and brand -Indigenous Roots First Nations are subject to different regulations than traditional businesses First Nations communities provide optionality for unique distribution channels

12 Distribution Recently received both a cultivation and a research license A 50/50 joint venture that will serve as the hub for Australia, New Zealand, and South East Asia STRATEGIC PRIORITIES Campus is located on 120 acres and will initially include a 20,000 sq. ft. purpose-built facility with an expected annualized production capacity of 2,000KG Facility will be designed considering both Good Production Practices and Good Manufacturing Practices (GMP)

13 Virtuous Cycle IP Portfolio

14 IP Portfolio GENETICS & METHODS New LPs need to source genetics from existing LPs, Cronos has over 150 unique cultivars Custom built CO2 extraction equipment removing the need for post-processing and maintaining natural balance of the plant STRATEGIC PRIORITIES GMP facilities & extraction labs allow for metabolite identification, separation and recombination to produce formulated products Unique light mapping systems and environmental controls allow for metabolite manipulation and increased yields Research projects with experts from Cornell University, University of Toronto, Hebrew University, Volcani Center, Fluence Bioengineering and P.L. Light Systems

15 Virtuous Cycle Brands

16 STRATEGIC PRIORITIES Brands We seek to offer accessible, high-quality products, building sincere relationships with our patients while supporting them with medications that can be life-changing At Peace Naturals our responsibility is to improve the lives of others, one patient at a time Peace will remain focused on the building and shaping the medical cannabis market

17 Brands STRATEGIC PRIORITIES Launched Original BC (OGBC) as a platform for two recreational brands One brand for mainstream and one brand for premium The Okanagan Valley in British Columbia is known for producing Canada s best cannabis, and we want to leverage that reputation Focus on a small-batch and crafted look and feel, perfected by our team of experts, never settling for shortcuts

18 Michael Gorenstein David Hsu William Hilson Eric Klein Jeff Jacobson Dr. Lasse Schulze President, CEO & Chairman Head of Operations Chief Financial Officer Head of Marketing Head of Business Development Head of Horticulture Former Partner at Alphabet Financial and operational Previously Regional CFO for Brand management at Government relations and 10+ years international Ventures LLC restructuring expertise Serono & Merck PepsiCo, Chobani, and Kraft regulatory expert experience in the M&A Law at Sullivan & Former VP at Deloitte CRG MSc in Clinical Biochemistry MBA from University of Chicago Founder of a Toronto Horticultural Industry Cromwell J.D. from University of Pennsylvania Law School Bachelor of Science in Business Management from Babson College and Honors Bachelor of Genetics Booth School of Business based marketing agency Founding member of Peace Naturals Ph.D. in Plant Physiology and Toxicology from the University of Toronto

19 Thank You Contact Information 720 King Street West, Suite 320 Toronto, Ontario M5V 2T3 Office: (416)